Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | HSD17B14 | Q9BPX1 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27075089 | 1.00 | HSD17B1 (0.39) | HSD17B1HSD17B2HSD17B14NR3C1ESR1 | |
| SCHEMBL25340267 | 0.84 | NR3C1 (0.55) | HSD17B1HSD17B2NR3C1ESR1ESR2 | |
| SCHEMBL27074772 | 0.83 | HSD17B1 (0.43) | HSD17B1HSD17B2HSD17B14NR3C1ESR1 | |
| SCHEMBL27074705 | 0.82 | HSD17B1 (0.42) | HSD17B1HSD17B2HSD17B14NR3C1PGR | |
| SCHEMBL27074701 | 0.75 | HSD17B1 (0.48) | HSD17B1HSD17B2HSD17B14NR3C1ESR1 | |
| SCHEMBL30572930 | 0.75 | NR3C1 (0.36) | NR3C1PGR | |
| SCHEMBL25340505 | 0.75 | NR3C1 (0.36) | NR3C1PGR | |
| SCHEMBL27074850 | 0.74 | NR3C1 (0.55) | NR3C1PGR | |
| SCHEMBL25341867 | 0.74 | MAPK8 (0.46) | NR3C1PGR | |
| SCHEMBL30728999 | 0.74 | NR3C1 (0.61) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | HSD17B1 3/4885HSD17B2 5/4885HSD17B14 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.